For patients with psoriasis receiving biologic therapy, residual inflammation (RI), defined as increased inflammatory markers in blood, characterized by high-sensitivity C-reactive protein, despite ...

Certain biologic therapies, such as ustekinumab, significantly effect hematological and lipid parameters in patients with psoriasis.

Discover a study in which researchers examined three international cohorts of patients with moderate-to-severe psoriasis ...

The study revealed the following findings: 36.3% of psoriasis patients had elevated high-sensitivity C-reactive protein ...

About 1 in 3 people with psoriasis who achieved clear skin with biologic drugs still had underlying inflammation that may ...

Skin symptoms may clear with biologics in psoriasis, but hidden internal inflammation often persists, contributing to major ...

New research shows that in patients with psoriasis, even though their skin responds well to treatment with biologics, ...

Innovent Biologics doses first participant in phase 3 clinical study of picankibart: San Francisco Friday, May 30, 2025, 12:00 Hrs [IST] Innovent Biologics, Inc, a world-class bio ...

The study reveals that patients with both T2D and psoriasis face a significantly elevated risk of developing renal conditions ...

A new clinical review explores the complexities of treating psoriasis during pregnancy and lactation highlighting limited ...